JP2003519683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003519683A5 JP2003519683A5 JP2001551848A JP2001551848A JP2003519683A5 JP 2003519683 A5 JP2003519683 A5 JP 2003519683A5 JP 2001551848 A JP2001551848 A JP 2001551848A JP 2001551848 A JP2001551848 A JP 2001551848A JP 2003519683 A5 JP2003519683 A5 JP 2003519683A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- trifluoromethyl
- hydroxyindole
- chlorobenzyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 229910052801 chlorine Inorganic materials 0.000 claims 12
- 239000000460 chlorine Substances 0.000 claims 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 11
- 239000000651 prodrug Substances 0.000 claims 11
- 229940002612 prodrugs Drugs 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 239000011737 fluorine Substances 0.000 claims 9
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 239000011630 iodine Substances 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 102100008428 CCL2 Human genes 0.000 claims 4
- 101700006000 CCL2 Proteins 0.000 claims 4
- 101710043203 P23p89 Proteins 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 230000003042 antagnostic Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FFJIOGAAFGBMMO-UHFFFAOYSA-N 1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 FFJIOGAAFGBMMO-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000004970 halomethyl group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- VHPDLTZTLBFZJT-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-6-fluoro-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(F)C=C2N1CC1=CC=C(Cl)C(Cl)=C1 VHPDLTZTLBFZJT-UHFFFAOYSA-N 0.000 claims 1
- CVJXQVZPWKDJFD-UHFFFAOYSA-N 1-[(3-bromo-4-chlorophenyl)methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(Cl)C(Br)=C1 CVJXQVZPWKDJFD-UHFFFAOYSA-N 0.000 claims 1
- AZZMKZQUHOQKOF-UHFFFAOYSA-N 1-[(3-bromo-4-fluorophenyl)methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(F)C(Br)=C1 AZZMKZQUHOQKOF-UHFFFAOYSA-N 0.000 claims 1
- YWENOMRUEZAFGD-UHFFFAOYSA-N 1-[(4-bromo-3-fluorophenyl)methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(Br)C(F)=C1 YWENOMRUEZAFGD-UHFFFAOYSA-N 0.000 claims 1
- DYOWZWIWUWQILS-UHFFFAOYSA-N 1-[[3-chloro-4-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(C(F)(F)F)C(Cl)=C1 DYOWZWIWUWQILS-UHFFFAOYSA-N 0.000 claims 1
- ASUIQMIBTSRRHL-UHFFFAOYSA-N 1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-5-hydroxy-3-iodoindole-2-carboxylic acid Chemical compound OC(=O)C1=C(I)C2=CC(O)=CC=C2N1CC1=CC=C(C(F)(F)F)C(F)=C1 ASUIQMIBTSRRHL-UHFFFAOYSA-N 0.000 claims 1
- VZHNQRSOIOXODL-UHFFFAOYSA-N 1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC=C2N1CC1=CC=C(C(F)(F)F)C(F)=C1 VZHNQRSOIOXODL-UHFFFAOYSA-N 0.000 claims 1
- IPNKCDSWDXVBCS-UHFFFAOYSA-N 1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxy-3-methoxyindole-2-carboxylic acid Chemical compound C12=CC=C(O)C=C2C(OC)=C(C(O)=O)N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 IPNKCDSWDXVBCS-UHFFFAOYSA-N 0.000 claims 1
- JERXCFGEKCNECK-UHFFFAOYSA-N 1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-6-fluoro-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(F)C=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 JERXCFGEKCNECK-UHFFFAOYSA-N 0.000 claims 1
- NPZKVFPFDJWZFD-UHFFFAOYSA-N 1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-7-fluoro-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=CC(F)=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 NPZKVFPFDJWZFD-UHFFFAOYSA-N 0.000 claims 1
- TZLPFOAQHIZWMN-UHFFFAOYSA-N 3-bromo-1-[[3-chloro-4-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=C(Br)C2=CC(O)=CC=C2N1CC1=CC=C(C(F)(F)F)C(Cl)=C1 TZLPFOAQHIZWMN-UHFFFAOYSA-N 0.000 claims 1
- PKHPHZXPWYGMCA-UHFFFAOYSA-N 3-bromo-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=C(Br)C2=CC(O)=CC=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 PKHPHZXPWYGMCA-UHFFFAOYSA-N 0.000 claims 1
- BMDQSNQWUHNZRT-UHFFFAOYSA-N 3-bromo-1-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=C(Br)C2=CC(O)=CC=C2N1CC1=CC=C(F)C(C(F)(F)F)=C1 BMDQSNQWUHNZRT-UHFFFAOYSA-N 0.000 claims 1
- FMTJTNFXYHDRRD-UHFFFAOYSA-N 3-chloro-1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=C(Cl)C2=CC(O)=CC=C2N1CC1=CC=C(C(F)(F)F)C(F)=C1 FMTJTNFXYHDRRD-UHFFFAOYSA-N 0.000 claims 1
- VKSKGPMWYOCWFW-UHFFFAOYSA-N 4,6-dichloro-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=C(Cl)C(O)=C(Cl)C=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 VKSKGPMWYOCWFW-UHFFFAOYSA-N 0.000 claims 1
- JGFMABXCOAPPOS-UHFFFAOYSA-N 4,6-difluoro-1-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=C(F)C(O)=C(F)C=C2N1CC1=CC=C(F)C(C(F)(F)F)=C1 JGFMABXCOAPPOS-UHFFFAOYSA-N 0.000 claims 1
- IPUPNCFHSUXZQC-UHFFFAOYSA-N 4-chloro-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=C(Cl)C(O)=CC=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 IPUPNCFHSUXZQC-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- XLSXVVWAGZFQMY-UHFFFAOYSA-N 5-acetyloxy-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(OC(=O)C)=CC=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 XLSXVVWAGZFQMY-UHFFFAOYSA-N 0.000 claims 1
- JOYQPINQNBHROU-UHFFFAOYSA-N 6-bromo-1-[(3,4-dichlorophenyl)methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(Br)C=C2N1CC1=CC=C(Cl)C(Cl)=C1 JOYQPINQNBHROU-UHFFFAOYSA-N 0.000 claims 1
- BEOZLFMCZQOJOJ-UHFFFAOYSA-N 6-bromo-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(Br)C=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 BEOZLFMCZQOJOJ-UHFFFAOYSA-N 0.000 claims 1
- GLHOHBQJNKZQSN-UHFFFAOYSA-N 6-chloro-1-[(3,4-dichlorophenyl)methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(Cl)C=C2N1CC1=CC=C(Cl)C(Cl)=C1 GLHOHBQJNKZQSN-UHFFFAOYSA-N 0.000 claims 1
- MZBARAFRMKJZRC-UHFFFAOYSA-N 6-chloro-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(Cl)C=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 MZBARAFRMKJZRC-UHFFFAOYSA-N 0.000 claims 1
- YUESWVLVTXPMEW-UHFFFAOYSA-N 6-chloro-1-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-5-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)C1=CC2=CC(O)=C(Cl)C=C2N1CC1=CC=C(F)C(C(F)(F)F)=C1 YUESWVLVTXPMEW-UHFFFAOYSA-N 0.000 claims 1
- PQODGLRZNILPBB-UHFFFAOYSA-N FC(C=1C=C(CN2C(=CC3=C(C(=CC=C23)O)F)C(=O)O)C=CC1Cl)(F)F.FC(C=1C=C(CN2C(=CC3=C(C(=CC=C23)O)F)C(=O)O)C=CC1F)(F)F Chemical compound FC(C=1C=C(CN2C(=CC3=C(C(=CC=C23)O)F)C(=O)O)C=CC1Cl)(F)F.FC(C=1C=C(CN2C(=CC3=C(C(=CC=C23)O)F)C(=O)O)C=CC1F)(F)F PQODGLRZNILPBB-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (14)
- 式(I)において:
R1は水素、フッ素または塩素であり;
R2は水素、塩素、臭素、ヨウ素またはメトキシであり;
R3はフッ素、塩素、臭素、ヨウ素であり;
R4はトリフルオロメチルであり;
R5およびR6は水素である、
請求項1に記載の化合物。 - 式(I)において:
R1は水素、フッ素または塩素であり;
R2は水素、塩素、臭素、ヨウ素またはメトキシであり;
R3はトリフルオロメチルであり;
R4はフッ素、塩素、臭素またはヨウ素であり;
R5およびR6は水素である、
請求項1に記載の化合物。 - 式(I)において:
R1は水素、フッ素または塩素であり;
R2は水素、塩素、臭素、ヨウ素またはメトキシであり;
R3およびR4はともにハロ、とりわけフッ素、塩素または臭素であるか、あるいはR3およびR4の一方が塩素であり、R3およびR4の他方がフッ素であり;
R5およびR6の一方または両方がハロである、
請求項1に記載の化合物。 - 下記:
N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−フルオロ−4−トリフルオロメチルベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−クロロ−4−トリフルオロメチルベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−ブロモ−4−クロロベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−フルオロ−4−ブロモベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−ブロモ−4−フルオロベンジル)−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−フルオロベンジル)−4−フルオロ−5−ヒドロキシインドール−2−カルボン酸
N−(3−トリフルオロメチル−4−クロロベンジル)−4−フルオロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−フルオロベンジル)−4,6−ジフルオロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3,4−クロロベンジル)−4,6−ジクロロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−フルオロベンジル)−3−ブロモ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−3−ブロモ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−クロロ−4−トリフルオロメチルベンジル)−3−ブロモ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−フルオロ−4−トリフルオロメチルベンジル)−3−クロロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−フルオロ− 4−トリフルオロメチルベンジル)−3−ヨード−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−3−メトキシ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−フルオロベンジル)−5−ヒドロキシ−6−クロロインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシ−6−クロロインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシ−7−フルオロインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシ−6−ブロモインドール−2−カルボン酸;
N−(3,4−ジクロロベンジル)−5−ヒドロキシ−6−ブロモインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシ−6−フルオロインドール−2−カルボン酸;
N−(3,4−ジクロロベンジル)−5−ヒドロキシ−6−フルオロインドール−2−カルボン酸;
N−(3,4−ジクロロベンジル)−5−ヒドロキシ−6−クロロインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−4−クロロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−4,6−ジクロロ−5−ヒドロキシインドール−2−カルボン酸;
N−(3−トリフルオロメチル−4−クロロベンジル)−5−アセトキシインドール−2−カルボン酸(N−(3−トリフルオロメチル−4−クロロベンジル)−5−ヒドロキシインドール−2−カルボン酸のプロドラッグ)
のいずれかである、請求項1に記載の化合物。 - 請求項1の化合物または薬学的に許容されるその塩またはプロドラッグの製造方法であって:
(a)式(II):
R1、R2、R5およびR6は請求項1に定義のものであり、Raはカルボキシまたはその保護された形態であり、Rbは水素または適当なヒドロキシ保護基である。〕の化合物を、式(III):
R3およびR4は請求項1に定義のものであり、Lは置換可能な基である。〕
の化合物と反応させること;
および所望によりその後:
(b) (i)式(I)の得られた化合物を別の式(I)化合物に変換すること;
(ii)任意の保護基を除去すること;または
(iii)薬学的に許容されるその塩またはプロドラッグを形成すること
を含む方法。 - 治療によってヒトまたは動物を処置する方法における使用のための、請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグ。
- 医薬としての使用のための、請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグ。
- 温血動物におけるMCP−1介在性効果に拮抗するための医薬として使用する、請求項9に記載の化合物。
- 薬学的に許容される賦形剤または担体とともに、請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグを含む医薬組成物。
- 温血動物におけるMCP−1介在性効果への拮抗のための医薬の製造における、請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグの使用。
- 炎症性疾患の処置方法であって、このような処置を必要とする宿主に請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグ、または請求項11に記載の医薬組成物を投与することを含む方法。
- MCP−1介在性効果を拮抗するような処置を必要とする温血動物におけるMCP−1介在性効果を拮抗する方法であって、該動物に有効量の請求項1〜6のいずれかに記載の化合物または薬学的に許容されるその塩またはプロドラッグ、または請求項11に記載の医薬組成物を投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0000626.2A GB0000626D0 (en) | 2000-01-13 | 2000-01-13 | Chemical compounds |
GB0000626.2 | 2000-01-13 | ||
PCT/GB2001/000069 WO2001051466A1 (en) | 2000-01-13 | 2001-01-11 | Indole derivatives as mcp-1 receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003519683A JP2003519683A (ja) | 2003-06-24 |
JP2003519683A5 true JP2003519683A5 (ja) | 2005-06-30 |
Family
ID=9883551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001551848A Pending JP2003519683A (ja) | 2000-01-13 | 2001-01-11 | Mcp−1受容体アンタゴニストとしてのインドール誘導体 |
Country Status (25)
Country | Link |
---|---|
US (1) | US20030144339A1 (ja) |
EP (1) | EP1252142A1 (ja) |
JP (1) | JP2003519683A (ja) |
KR (1) | KR20020064375A (ja) |
CN (1) | CN1395565A (ja) |
AR (1) | AR026839A1 (ja) |
AU (1) | AU780992B2 (ja) |
BG (1) | BG106894A (ja) |
BR (1) | BR0107404A (ja) |
CA (1) | CA2393592A1 (ja) |
CO (1) | CO5271703A1 (ja) |
EE (1) | EE200200394A (ja) |
GB (1) | GB0000626D0 (ja) |
HK (1) | HK1049486A1 (ja) |
HU (1) | HUP0300694A3 (ja) |
IL (1) | IL150272A0 (ja) |
IS (1) | IS6429A (ja) |
MX (1) | MXPA02006611A (ja) |
NO (1) | NO20023380L (ja) |
NZ (1) | NZ519312A (ja) |
PL (1) | PL356031A1 (ja) |
RU (1) | RU2002121636A (ja) |
SK (1) | SK10072002A3 (ja) |
WO (1) | WO2001051466A1 (ja) |
ZA (1) | ZA200204354B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
WO2004069809A1 (en) * | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Mercaptoimidazoles as ccr2 receptor antagonists |
JP4945243B2 (ja) * | 2004-09-13 | 2012-06-06 | 株式会社クレハ | 熱発泡性マイクロスフェアー、その製造方法、その使用、それを含む組成物、及び物品 |
ATE448230T1 (de) | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
US7507736B2 (en) | 2007-02-07 | 2009-03-24 | Hoffmann-La Roche Inc. | Indol-2-yl-piperazin-1-yl-methanone derivatives |
EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
WO2023224981A1 (en) * | 2022-05-17 | 2023-11-23 | Inipharm, Inc. | Hsd17b13 inhibitors and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4529724A (en) * | 1983-10-11 | 1985-07-16 | Mcneilab, Inc. | 6H-indolo[2,1-c][1,4]benzodiazepines and 12-oxo derivatives useful as antihypertensives |
DE3907388A1 (de) * | 1989-03-08 | 1990-09-13 | Kali Chemie Pharma Gmbh | Verfahren zur herstellung von indolcarbonsaeurederivaten |
US5272145A (en) * | 1989-08-22 | 1993-12-21 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes |
US5081145A (en) * | 1990-02-01 | 1992-01-14 | Merck Frosst Canada, Inc. | Indole-2-alkanoic acids compositions of and anti allergic use thereof |
US5389650A (en) * | 1991-09-30 | 1995-02-14 | Merck Frosst Canada, Inc. | (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5308850A (en) * | 1991-09-30 | 1994-05-03 | Merck Frosst Canada, Inc. | (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5273980A (en) * | 1991-09-30 | 1993-12-28 | Merck Frosst Canada Inc. | Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
US5290798A (en) * | 1991-09-30 | 1994-03-01 | Merck Frosst Canada, Inc. | (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis |
US5190968A (en) * | 1991-09-30 | 1993-03-02 | Merck Frosst Canada, Inc. | (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis |
US5288743A (en) * | 1992-11-20 | 1994-02-22 | Abbott Laboratories | Indole carboxylate derivatives which inhibit leukotriene biosynthesis |
US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
US5686481A (en) * | 1993-12-21 | 1997-11-11 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
US5482960A (en) * | 1994-11-14 | 1996-01-09 | Warner-Lambert Company | Nonpeptide endothelin antagonists |
US5684032A (en) * | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
WO1997035572A1 (en) * | 1996-03-28 | 1997-10-02 | Smithkline Beecham Corporation | Carboxylic acid indole inhibitors of chemokines |
EP0927167A1 (en) * | 1996-08-14 | 1999-07-07 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
GB9716657D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
GB9716656D0 (en) * | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
GB9803226D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
GB9803228D0 (en) * | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
GB9902461D0 (en) * | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
-
2000
- 2000-01-13 GB GBGB0000626.2A patent/GB0000626D0/en not_active Ceased
-
2001
- 2001-01-11 EE EEP200200394A patent/EE200200394A/xx unknown
- 2001-01-11 CN CN01803645A patent/CN1395565A/zh active Pending
- 2001-01-11 EP EP01900494A patent/EP1252142A1/en not_active Withdrawn
- 2001-01-11 IL IL15027201A patent/IL150272A0/xx unknown
- 2001-01-11 WO PCT/GB2001/000069 patent/WO2001051466A1/en not_active Application Discontinuation
- 2001-01-11 SK SK1007-2002A patent/SK10072002A3/sk unknown
- 2001-01-11 NZ NZ519312A patent/NZ519312A/en unknown
- 2001-01-11 AU AU25324/01A patent/AU780992B2/en not_active Ceased
- 2001-01-11 RU RU2002121636/04A patent/RU2002121636A/ru not_active Application Discontinuation
- 2001-01-11 MX MXPA02006611A patent/MXPA02006611A/es unknown
- 2001-01-11 HU HU0300694A patent/HUP0300694A3/hu unknown
- 2001-01-11 BR BR0107404-0A patent/BR0107404A/pt not_active IP Right Cessation
- 2001-01-11 US US10/169,717 patent/US20030144339A1/en not_active Abandoned
- 2001-01-11 PL PL01356031A patent/PL356031A1/xx not_active Application Discontinuation
- 2001-01-11 JP JP2001551848A patent/JP2003519683A/ja active Pending
- 2001-01-11 CA CA002393592A patent/CA2393592A1/en not_active Abandoned
- 2001-01-11 KR KR1020027009021A patent/KR20020064375A/ko not_active Application Discontinuation
- 2001-01-12 AR ARP010100144A patent/AR026839A1/es not_active Application Discontinuation
- 2001-01-15 CO CO01002379A patent/CO5271703A1/es not_active Application Discontinuation
-
2002
- 2002-05-30 ZA ZA200204354A patent/ZA200204354B/en unknown
- 2002-06-19 IS IS6429A patent/IS6429A/is unknown
- 2002-07-02 BG BG106894A patent/BG106894A/bg unknown
- 2002-07-12 NO NO20023380A patent/NO20023380L/no not_active Application Discontinuation
-
2003
- 2003-03-06 HK HK03101662.2A patent/HK1049486A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2335493C2 (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
JP2002536359A5 (ja) | ||
JP2003532731A5 (ja) | ||
JP2006182786A5 (ja) | ||
JP2018524298A5 (ja) | ||
IL175716A (en) | 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation | |
JP2019503365A5 (ja) | ||
JP2017531038A5 (ja) | ||
CA2432121A1 (en) | Nitric oxide synthase inhibitor phosphate salt | |
JP2011507896A5 (ja) | ||
JP2009502743A5 (ja) | ||
JP2014526503A5 (ja) | ||
JP2008534453A5 (ja) | ||
RU2007133802A (ru) | Кристаллические формы производной имидазола | |
RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
JP2006503850A5 (ja) | ||
JP2007507494A5 (ja) | ||
CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
JP2006501201A5 (ja) | ||
JP2003519683A5 (ja) | ||
JP2013507426A5 (ja) | ||
JP2003503449A5 (ja) | ||
JP2010500284A5 (ja) | ||
CN110770247A (zh) | 治疗和预防肾损害 | |
AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 |